Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test? @eular_org @Janetbirdope @RheumNow What does #MedTwitter think? https://t.co/bqwPU8XX5S

• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1

#EULAR2024 JAK-i Debate. @Janetbirdope [Pro Regulatory Safety Measures] - to do no harm esp since there are other alternatives - supported by RCT - although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg

• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1
• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1

#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew Topic: can observational study debunk RCT? This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA

• https://twitter.com/Yuz6Yusof/status/1800867028850577678/photo/1

The great debate on JAKi risk and special warnings And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew Get the popcorn ready 🍿 #EULAR2024 https://t.co/z50Ob8q0i0

• https://twitter.com/AurelieRheumo/status/1800866706077958184/photo/1

JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis? A JAK inhibitor outperformed TNF blockers for substantially reducing RA symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found. https://t.co/7BhFSwb1Ns https://t.co/Hf31OPgE0M

• JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis? | RheumNow